Description

The HOYA TORIC IOL VIVINEX ISERT is a sophisticated intraocular lens designed to enhance visual outcomes for patients undergoing cataract surgery with astigmatism. Crafted by HOYA Surgical Optics, this lens offers a range of advanced features tailored to meet the needs of ophthalmic professionals.

Advanced Material

• Glistening-Free Hydrophobic Acrylic: Ensures long-term optical clarity.
• UV and Blue Light Filters: Provides additional protection for the eye.

Optic Design

• Biconvex with Anterior Aspheric Surface: Enhances image quality by partially compensating for corneal spherical aberration.
• Posterior Toric Surface: Specifically designed for effective astigmatism correction.
• Sharp, Square Optic Edge: Minimizes posterior capsule opacification (PCO).

Haptic Design

• Textured Surface: Made from the same material as the optic for enhanced stability.
• Consistent Centration: Contributes to the lens's reliable performance post-implantation.

Dimensions

• Optic Diameter: 6.00 mm
• Overall Length: 13.00 mm

Power Range

• Spherical Power: +10.00 to +30.00 diopters (D) in 0.50 D increments.
• Cylinder Power: Ranges from 1.00 to 6.00 D, tailored for precise astigmatism correction.

Rotational Stability

• Exceptional Stability: Median rotation of 1.1° with 100% of lenses showing ≤5° rotation up to six months post-implantation.

Injector System

• Preloaded in Vivinex™ iSert® or multiSert™ Systems: Facilitates consistent and predictable IOL delivery.
• Recommended Incision Size: 2.20 mm

Optical Constants

• Nominal A-Constant: 118.9
• Supported by HOYA Toric Calculator: Incorporates advanced formulas for precise power calculation.

Clinical Benefits

• Improved Visual Clarity: Through precise astigmatism correction.
• Reduced PCO Incidence: Leading to lower Nd:YAG capsulotomy rates.
• High Biocompatibility: Ensures long-term stability and performance.

Indications

Intended for use by healthcare professionals in cataract surgery patients requiring astigmatism correction. Available in multiple countries, including Saudi Arabia, UAE, Oman, Qatar, Kuwait, and Lebanon.

For comprehensive indications and contraindications, healthcare professionals should refer to the Instructions For Use.